What is the best medication to treat primary hyperaldosteronism (aldosterone excess)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Best Blood Pressure Medication for Primary Hyperaldosteronism

Spironolactone is the first-line medication for treating primary hyperaldosteronism, with a starting dose of 25-50 mg daily that can be titrated up to 100-400 mg daily as needed for blood pressure control. 1, 2, 3

Treatment Algorithm Based on Disease Subtype

For Bilateral Disease (Idiopathic Hyperaldosteronism)

  • Start spironolactone 25-100 mg daily as the cornerstone of medical therapy 1, 2, 3
  • Titrate the dose at two-week intervals based on blood pressure response 3
  • Maximum doses of 300-400 mg daily may be necessary for adequate control 2, 4
  • Spironolactone is specifically identified as the preferred agent for primary aldosteronism in major guidelines 1, 2

For Unilateral Disease

  • Laparoscopic adrenalectomy remains the treatment of choice for surgical candidates 2, 5
  • However, medical therapy with spironolactone achieves equivalent long-term outcomes to surgery in terms of blood pressure control, cardiovascular outcomes, and kidney function 5
  • For patients who are not surgical candidates (elderly, multiple comorbidities, patient preference), proceed directly to spironolactone therapy 2, 5

Alternative Medication: Eplerenone

Eplerenone (50-100 mg daily in 1-2 doses) is the preferred alternative when patients develop sexual side effects on spironolactone 1, 2

  • Eplerenone has equal effectiveness to spironolactone for blood pressure control 2
  • It causes significantly less gynecomastia, breast tenderness, erectile dysfunction, and menstrual irregularities compared to spironolactone 1, 2, 6
  • The main limitation is that eplerenone often requires twice-daily dosing for adequate blood pressure lowering 1

Critical Safety Monitoring

Before Initiating Treatment

  • Verify serum potassium ≤5.0 mEq/L 2
  • Confirm serum creatinine <2.0-2.5 mg/dL or eGFR >30 mL/min 2
  • Discontinue all potassium supplements 2

Monitoring Schedule

  • Check potassium and creatinine at 3 days, 1 week, then monthly for the first 3 months 2
  • Subsequently monitor every 3 months if stable 2

Common Pitfalls and Contraindications

Avoid These Dangerous Combinations

  • Do not combine with potassium supplements or potassium-sparing diuretics due to severe hyperkalemia risk 1, 2, 3
  • Use extreme caution when combining with ACE inhibitors or ARBs - requires close monitoring for hyperkalemia 1, 2, 3
  • Avoid NSAIDs or COX-2 inhibitors due to increased risk of hyperkalemia and renal dysfunction 2, 3
  • Do not use with lithium - spironolactone reduces lithium clearance and causes toxicity 3

Renal Function Considerations

  • Use with caution if eGFR <45 mL/min 1, 2
  • Avoid in significant renal dysfunction (creatinine >2.5 mg/dL) 2

Additional Agents for Resistant Cases

If blood pressure remains uncontrolled on maximum-dose spironolactone:

  • Add amiloride or triamterene (potassium-sparing diuretics) 4
  • Add calcium channel blockers (amlodipine, nifedipine) 1, 4

Why This Matters for Outcomes

Early diagnosis and treatment with mineralocorticoid receptor antagonists reverses aldosterone-specific target organ damage, including left ventricular hypertrophy, albuminuria, and carotid intima-media thickness 5

Delayed treatment leads to irreversible vascular remodeling that causes residual hypertension and cardiovascular/renal complications even after appropriate treatment is initiated 2, 5

Blood pressure improves in virtually 100% of patients treated with adequate doses of mineralocorticoid receptor antagonists, with complete normalization occurring in approximately 50% of cases 2, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management and Treatment of Primary Hyperaldosteronism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of primary aldosteronism.

Best practice & research. Clinical endocrinology & metabolism, 2010

Guideline

Medical Management of Primary Aldosteronism for Elevated Blood Pressure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Primary aldosteronism - treatment options.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.